Myovant Sciences Ltd. financial data

Industry
Pharmaceutical Preparations
Location
Suite 1, 3 Rd Floor, 11 12 St. James Square, London, United Kingdom
State of incorporation
CA
Fiscal year end
March 31
Latest financial report
10-Q - Q4 2022 - Jan 26, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 181 % -22.7%
Quick Ratio 8.41 % +382%
Debt-to-equity -192 % +30%
Return On Equity 36.2 % -37.7%
Return On Assets -39.4 % -18.1%
Operating Margin -38.8 % +63.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 97.2M shares +3.55%
Common Stock, Shares, Outstanding 97M shares +3.6%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 96.9M shares +3.62%
Weighted Average Number of Shares Outstanding, Diluted 96.9M shares +3.62%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 379M USD +91.5%
Research and Development Expense 107M USD +2.3%
Operating Income (Loss) -147M USD +30.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -162M USD +28.2%
Income Tax Expense (Benefit) 21.5M USD +968%
Net Income (Loss) Attributable to Parent -184M USD +19.4%
Earnings Per Share, Basic -1.92 USD/shares +22.3%
Earnings Per Share, Diluted -1.92 USD/shares +22.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 251M USD -45.3%
Marketable Securities, Current 23.8M USD -65.9%
Cash, Cash Equivalents, and Short-term Investments 274M USD -48%
Accounts Receivable, after Allowance for Credit Loss, Current 41M USD +117%
Inventory, Net 30.1M USD +347%
Assets, Current 387M USD -32.7%
Property, Plant and Equipment, Net 2.55M USD -13.8%
Operating Lease, Right-of-Use Asset 7.1M USD -15.6%
Other Assets, Noncurrent 7.29M USD -59.9%
Assets 404M USD -33.2%
Accounts Payable, Current 12.2M USD +0.72%
Employee-related Liabilities, Current 23.5M USD +5.92%
Liabilities, Current 246M USD -8.66%
Operating Lease, Liability, Noncurrent 5.48M USD -28.1%
Other Liabilities, Noncurrent 1.72M USD +363%
Liabilities 962M USD -7.23%
Retained Earnings (Accumulated Deficit) -1.38B USD -15.4%
Stockholders' Equity Attributable to Parent -558M USD -29.1%
Liabilities and Equity 404M USD -33.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -76M USD +32.8%
Net Cash Provided by (Used in) Financing Activities 1.19M USD -71.2%
Net Cash Provided by (Used in) Investing Activities -5.74M USD +92.3%
Common Stock, Shares Authorized 564M shares 0%
Common Stock, Shares, Issued 97M shares +3.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -80.6M USD +56.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 257M USD -45.1%
Deferred Tax Assets, Valuation Allowance 244M USD +17.5%
Deferred Tax Assets, Gross 246M USD +17.1%
Operating Lease, Liability 9.19M USD -16.4%
Depreciation 335K USD +4.36%
Payments to Acquire Property, Plant, and Equipment 72K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -184M USD +19.4%
Lessee, Operating Lease, Liability, to be Paid 11.5M USD -20.9%
Operating Lease, Liability, Current 2.7M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.05M USD -2.37%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.13M USD +3.27%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.3M USD -34.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.41M USD -21.1%
Unrecognized Tax Benefits 5.22M USD +18.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.48M USD +3.03%
Additional Paid in Capital 836M USD +7.45%
Deferred Tax Assets, Net of Valuation Allowance 2.27M USD -15.6%
Share-based Payment Arrangement, Expense 41.5M USD -32.9%
Interest Expense 18.6M USD +33.3%